The HLA Alleles B*0801 and DRB1*0301 Are Associated with Dermatitis Herpetiformis in a Chinese Population-Reference-Cited by-同舟云学术

The HLA Alleles B*0801 and DRB1*0301 Are Associated with Dermatitis Herpetiformis in a Chinese Population

Published:2016-02 Issue:2 Volume:136 Page:530-532
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Sun Yonghu,Lin Yan,Yang Baoqi,Wang Chuan,Fu Xi’an,Bao Fangfang,Yu Gongqi,Zhang Qilin,Wang Zhenzhen,Zhou Guizhi,Chen Xuechao,Wu Mei,Wang Guangjin,Liu Hong,Liu Jianjun,Zhang Furen

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference16 articles.

1. High-resolution, high-throughput HLA genotyping by next-generation sequencing;Bentley;Tissue Antigens,2009

2. Dermatitis herpetiformis: part I. Epidemiology, pathogenesis, and clinical presentation;Bolotin;J Am Acad Dermatol,2011

3. HLA class II region genes and susceptibility to dermatitis herpetiformis: DPB1 and TAP2 associations are secondary to those of the DQ subregion;Hall;Eur J Immunogenet,1996

4. Alterations in HLA-DP and HLA-DQ antigen frequency in patients with dermatitis herpetiformis;Hall;J Invest Dermatol,1989

5. HLA-B8 and dermatitis herpetiformis in patients with IgA deposits in skin;Katz;Arch Dermatol,1977

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted serum proteome profiling reveals nicotinamide adenine dinucleotide phosphate (NADPH)-related biomarkers to discriminate linear IgA bullous disorder from dermatitis herpetiformis;Clinical Immunology;2024-08

2. Targeted Serum Proteome Profiling Reveals Nicotinamide Adenine Dinucleotide Phosphate (NADPH)-Related Biomarkers to Discriminate Linear IgA Bullous Disorder from Dermatitis Herpetiformis;2024

3. Dermatitis herpetiformis;The Rose and Mackay Textbook of Autoimmune Diseases;2024

4. Dermatitis herpetiformis;Pediatric and Adult Celiac Disease;2024

5. Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders;Medicina;2023-11-04